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Supplementary Figure 1. Genotype principal component analysis of OCAC samples and 1000 
Genomes. X and Y axes display the number of standard deviations from 1000 Genomes EUR 
populations. Dotted lines enclose the samples used in this study.
Study Name Country 
 






Australian Cancer Study  Australia ACS 175 104 7 22 9 89 32 166 
Australian Ovarian Cancer Sutidy Australia AOC 802 448 35 84 43 409 118 714 
Bavarian Ovarian Cancer Cases and Controls Germany BAV 142 56 8 13 6 42 10 93 
Belgium Ovarian Cancer Study Belgium BEL 1348 194 23 22 23 182 17 274 
Diseases of the Ovary and their Evaluation USA DOV 1119 293 18 84 29 235 136 515 
Diseases of the Ovary and their Evaluation       USA DVE 368 233 8 64 36 200 78 389 
Germany Ovarian Cancer Study Germany GER 413 95 21 21 6 68 59 189 
Hawaii Ovarian Cancer Study USA HAW 156 38 3 12 5 36 2 60 
Hannover-Jena Ovarian Cancer Study Germany HJO 273 140 9 26 4 107 116 266 
Hannover-Minsk Ovarian Cancer Study Germany HMO 138 50 7 12 1 1 121 142 
Helsinki Ovarian Cancer Study Finland HOC 447 113 45 28 13 0 135 221 
Hormones and Ovarian Cancer Prediction USA HOP 1464 377 30 84 42 333 145 654 
Danish Malignant Ovarian Tumor Study Denmark MAL 828 272 42 54 33 183 53 440 
Mayo Clinic Ovarian Cancer Case Control Study USA MAY 10 9 0 1 0 9 0 10 
Melbourne Collaborative Cohort Study Australia MCC 65 34 7 7 6 19 21 63 
MD Anderson Ovarian Cancer Study USA MDA 384 190 27 28 4 135 179 373 
Memorial Sloan Kettering Cancer Center USA MSK 593 382 0 20 18 343 73 467 
North Carolina Ovarian Cancer Study USA NCO 172 147 18 35 24 132 50 269 
New England Case-Control Study USA NEC 979 371 41 140 33 331 60 634 
Nurses' Health Study I and II USA NHS 425 68 7 14 6 0 100 127 
New Jersey Ovarian Cancer Study USA NJO 180 100 7 27 20 80 27 169 
University of Bergen, Haukeland University Hospital, 
Norway 
Norway NOR 370 135 15 27 11 85 87 237 
Nijmegen Ovarian Cancer Study Netherlands NTH 323 116 33 64 20 64 52 255 
Ovarian Cancer in Alberta and British Columbia Canada OVA 748 344 26 103 57 0 445 631 
Polish Ovarian Cancer Study Poland POC 417 199 33 39 9 0 341 422 
Polish Ovarian cancer Case Control Study (NCI) Poland POL 186 21 4 10 2 15 11 42 
UK Studies of Epidemiology and Risk Factors in Cancer 
Heredity (SEARCH) Ovarian Cancer Study 
UK SEA 1196 162 38 24 28 104 71 271 
UK Studies of Epidemiology and Risk Factors in Cancer 
Heredity (SEARCH) Ovarian Cancer Study 
UK SEB 4826 11 5 5 0 4 15 29 
Southampton Ovarian Cancer Study UK SOC 0 102 33 62 11 72 79 267 
Family Registry for Ovarian Cancer AND Genetic 
Epidemiology of Ovarian Cancer 
USA STA 313 154 16 32 20 135 35 251 
Familial Ovarian Tumor Study Canada TOR 74 8 1 7 2 0 11 21 
UC Irvine Ovarian Cancer Study USA UCI 367 166 19 48 23 143 32 277 
UK Ovarian Cancer Population Study UK UKO 1103 117 24 32 25 93 51 236 
Los Angeles County Case-Control Studies of Ovarian 
Cancer 
USA USC 1047 447 44 79 35 341 161 689 
Warsaw Ovarian Cancer Study Poland WOC 203 132 8 20 17 131 25 202 
 Total*    21654 5828 662 1350 621 4121 2948 10065 
Supplementary Table 1. Description of individual OCAC studies and case‐control sample size. *Numbers differ from Table 1 in main manuscript, as these 
ones reflect the total number before Identity by descent (IBD) <0.10 filtering.
 Supplementary Figure 2. Contribution to the heritability by chromosome versus expected. Confidence intervals [0.05,0.95] 
were approximated through jackknifing up to 1000 times 
 
 
